Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
DANVERS, Mass., April 13, 2017 -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, May 4, 2017, the Company will release financial results for the fourth quarter of fiscal 2017. The Company will host a conference call to discuss the results on Thursday, May 4, 2017, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11 a.m. EDT May 4, 2017 through 11:00 a.m. EDT on May 7, 2017. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 3991529.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
For further information please contact: Ingrid Goldberg Director, Investor Relations 978-646-1590 [email protected]
